Add BrightSurf on Google Email

Destroying tumor cells: Targeted immunotherapy using injectable materials

Researchers at TIBI developed a minimally invasive method for targeted delivery of immunotherapeutic treatments, resulting in slower tumor growth and higher activation of T-cells. The injectable gelatin biomaterial containing silicate nanoplatelets showed sustained drug release and controlled ICI delivery.

SourceTerasaki Institute for Biomedical Innovation·JournalACS Applied Materials & Interfaces·TypeExperimental study·DateAug 1, 2022
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Moffitt researchers use mathematical modeling to explain immunotherapy responses

Researchers at Moffitt Cancer Center used mathematical modeling to study the impact of tumor size, immune cell populations, and interactions on cancer treatment outcomes. The models predicted optimal therapeutic approaches for different types of therapies, including cytotoxic chemotherapy and immunotherapies.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalJournal for ImmunoTherapy of Cancer·TypeComputational simulation/modeling·DateJul 26, 2022

Oncotarget | Predicting cancer immunotherapy response from gut microbiomes using machine learning models

A new study uses machine learning models to predict cancer patients' responses to immunotherapy based on their gut microbiome features. The research identifies common gut bacterial taxa associated with responders versus non-responders, providing a potential tool for distinguishing and predicting immunotherapy responders.

SourceImpact Journals LLC·JournalOncotarget·TypeComputational simulation/modeling·DateJul 19, 2022
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Anti-rejection medication and immunotherapy kicks cancer and protects kidney transplants

Researchers at the University of South Australia have discovered that combining anti-rejection medication with immune checkpoint inhibitors can significantly reduce the risk of organ rejection and eliminate cancer cells in a quarter of patients. The study involved 22 patients with renal transplants and incurable locally advanced or met...

SourceUniversity of South Australia·JournalThe Lancet Oncology·TypeExperimental study·DateJul 18, 2022

Study suggests that c. difficile drives some colorectal cancers

Researchers at Johns Hopkins Medicine found that Clostridioides difficile (C. difficile) bacteria may cause colorectal cancer in younger adults. The bacterium causes serious diarrheal infections and is linked to approximately 500,000 infections annually in the US.

SourceJohns Hopkins Medicine·JournalCancer Discovery·DateJul 14, 2022
Apple MacBook Pro 14-inch (M4 Pro)

Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.

Genetic discovery to improve lung cancer treatment

Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.

SourceEdith Cowan University·JournalEuropean Journal of Cancer·TypeRandomized controlled/clinical trial·DateJul 13, 2022

Cleveland Clinic research suggests tumors with specific genetic mutations are sensitive to immunotherapy

Researchers at Cleveland Clinic discovered that pathogenic POLE/POLD1 genetic mutations in tumors lead to a high level of immune cell infiltration and improved response to immune checkpoint blockade therapy. The study's findings contribute to the growing list of discoveries that prove certain classes of drugs are more effective based o...

SourceCleveland Clinic·JournalNature Genetics·DateJul 12, 2022
Creality K1 Max 3D Printer

Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.

New classification system proposed for colorectal cancer to guide treatment and clinical trials

A new classification system for colorectal cancer has been proposed, grouping cancers into five subtypes based on epithelial status, microsatellite status, and fibrosis. This update could inform targeted drug development efforts and improve treatment approaches for patients with different biological characteristics.

SourceSingHealth·JournalNature Genetics·TypeRandomized controlled/clinical trial·DateJul 1, 2022

Scientists prevent “exhaustion” in cancer-fighting T cells

Researchers at Gladstone Institutes and Stanford University identified key genes linked to T cell exhaustion. They discovered how to block these genes, resulting in healthier T cells and smaller tumors in mice with cancer. This breakthrough may lead to improved immune-based treatments for cancer patients.

SourceGladstone Institutes·JournalCancer Cell·DateJun 28, 2022

Oncotarget | New oncology-focused papers published in Volume 13

This volume of Oncotarget features groundbreaking research on various cancers, including breast, lung, colorectal, and neuroblastoma, as well as novel drug targets for bladder cancer. The studies also delve into the role of BRCA in breast and colorectal cancers.

SourceImpact Journals LLC·JournalOncotarget·DateJun 23, 2022
Meta Quest 3 512GB

Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.

‘Cellular brake’ offers clue to autoimmune response during immunotherapy

Researchers at the University of Birmingham have identified a 'cellular brake' protein that may help prevent autoimmune responses in lung cancer patients undergoing immunotherapy treatment. This finding could enable clinicians to closely monitor high-risk patients and develop preventative strategies.

SourceUniversity of Birmingham·JournalNature Communications·TypeExperimental study·DateJun 13, 2022

Early, encouraging data for glioblastoma treatment reported at ASCO

Researchers have reported encouraging early-stage data for the Phase 1 clinical trial of INB-200, a gamma-delta T cell-based immunotherapy. All patients enrolled in the trial have exceeded their expected progression-free survival, with two patients exceeding overall survival as well. The treatment shows promising activity against gliob...

SourceUniversity of Alabama at Birmingham·TypeExperimental study·DateJun 10, 2022
Nikon Monarch 5 8x42 Binoculars

Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.

Cancer: The double advantage of killer T-cells

Researchers found that 'killer' T-cells used in immunotherapy can also destroy tumour lymphatic vessels, greatly reducing the risk of metastasis. This synergistic effect could increase treatment effectiveness against cancers with high lymphangiogenesis.

SourceUniversité de Genève·JournalScience Advances·TypeNews article·DateJun 9, 2022

Cancer and immunotherapy – a game of cat and mouse

A recent study published in Cell Reports Medicine reveals that a gene family is involved in immunotherapy resistance, allowing tumor cells to evade immune detection. Inhibiting this gene family, including RNF31, makes tumor cells more susceptible to immune cell destruction.

SourceNetherlands Cancer Institute·JournalCell Reports Medicine·DateJun 9, 2022
Apple AirPods Pro (2nd Generation, USB-C)

Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.

NUS Yong Loo Lin School of Medicine and Xiamen University researchers use nanotechnology to destroy and prevent relapse of solid tumour cancers

Researchers at NUS Yong Loo Lin School of Medicine and Xiamen University have developed a novel nanovaccine that achieves complete clearance of solid tumors and induces long-lasting immune memory. The vaccine stimulates anti-tumor immunity by presenting antigens in a way that traditional vaccines cannot.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalNature Nanotechnology·DateJun 6, 2022

Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma

Researchers at MD Anderson Cancer Center found distinct gut microbiome signatures associated with immunotherapy response in patients with newly diagnosed glioblastoma. The study identified a link between gut microbiome signatures and immune checkpoint blockade response in melanoma, NSCLC, and sarcoma.

SourceUniversity of Texas M. D. Anderson Cancer Center·DateJun 6, 2022
Celestron NexStar 8SE Computerized Telescope

Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.

Sanoff offers perspective on a promising rectal cancer study in the New England Journal of Medicine

A recent study published in the New England Journal of Medicine found that dostarlimab was effective in treating a subtype of rectal cancer, showing remarkable responses and resolving difficult symptoms. The treatment offers a more effective and less toxic alternative to traditional chemotherapy and radiation.

SourceUNC Lineberger Comprehensive Cancer Center·JournalNew England Journal of Medicine·TypeCommentary/editorial·DateJun 5, 2022

Trial examines combo immunotherapy for treatment-resistant ovarian cancer

A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.

SourceUniversity of Cincinnati·DateJun 4, 2022

ASCO22: Lung cancer therapy could help patients live longer

A Phase II clinical trial found that an immunotherapy drug combination extended the lives of patients with non-small cell lung cancer, improving survival by 14.5 months compared to standard care therapy. The treatment also reduced chemotherapy use and side effects.

SourceCedars-Sinai Medical Center·JournalJournal of Clinical Oncology·DateJun 3, 2022

Novel immunotherapy mechanism suppresses breast cancer development

Researchers at Massachusetts General Hospital discovered a novel immunotherapy mechanism that uses CD4+ T helper 2 cells to suppress breast cancer development. These cells force breast cancer cells to revert to benign breast gland cells, providing new insights into the treatment of this disease.

SourceMassachusetts General Hospital·JournalJournal of Experimental Medicine·TypeExperimental study·DateJun 3, 2022
GoPro HERO13 Black

GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.

New drug combination lengthened survival for some with lung cancer

A new drug combination of ramucirumab and pembrolizumab significantly extended overall survival in advanced non-small cell lung cancer patients who had progressed on prior immunotherapy. The study found a 31% reduction in risk of death compared to standard therapy, with median overall survival times of 14.5 months.

SourceSWOG Cancer Research Network·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJun 3, 2022

Joining the fight against non-small cell lung cancer

Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.

SourceUniversity of Missouri-Columbia·JournalScientific Reports·DateJun 2, 2022

Biomarker in liquid biopsy for lung cancer appears more accurate in predicting immunotherapy response than tumor biopsy

Researchers validated a liquid biopsy test as a better predictor of immunotherapy response in lung cancer patients compared to traditional tumor biopsies. The test measures the PD-L1 biomarker in blood, showing improved accuracy in predicting treatment outcomes and survival.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of Experimental & Clinical Cancer Research·DateJun 2, 2022

Discovery could lead to better cancer immunotherapy

Researchers at Washington State University have discovered that a specific population of CD4-positive helper T cells initiates antitumor immunity defenses, which can enhance the effectiveness of killer cell attacks on cancer cells. This finding holds promise for improving cancer immunotherapy response rates.

SourceWashington State University·JournalThe Journal of Immunology·DateMay 31, 2022

A nanoparticle and inhibitor trigger the immune system, outsmarting brain cancer

Researchers at Michigan Medicine developed a nanoparticle-based inhibitor that successfully triggers the immune system to eliminate brain tumors in mouse models. The approach breaks the shield built by glioma cells around the immune system, allowing the immune cells to attack and delay tumor progression.

SourceMichigan Medicine - University of Michigan·JournalACS Nano·TypeExperimental study·DateMay 26, 2022
Apple Watch Series 11 (GPS, 46mm)

Apple Watch Series 11 (GPS, 46mm) tracks health metrics and safety alerts during long observing sessions, fieldwork, and remote expeditions.

Killing cancers with Z-DNA: A new approach to treating therapy resistant tumors that targets a very-specific cell-death pathway

Scientists have discovered a small molecule that bypasses ADAR1 suppression and directly activates tumor cell death by ZBP1, inducing highly immunogenic cell death and destroying fibroblasts supporting tumor growth. This approach has the potential to improve the effectiveness of immunotherapy in treating therapy-resistant tumors.

SourceInsideOutBio·JournalNature·TypeExperimental study·DateMay 25, 2022

Researchers find new mechanism to turn on cancer-killing T cells

Researchers at the University of Chicago Medicine Comprehensive Cancer Center and the University of Amsterdam have identified a new mechanism that prompts T cell responses, including MHC-I cross-dressing. This discovery may lead to improved vaccine design and targeted cancer treatment strategies.

SourceUniversity of Chicago Medical Center·JournalImmunity·TypeObservational study·DateMay 25, 2022
Davis Instruments Vantage Pro2 Weather Station

Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.

How fat could help in tailoring cancer treatment plans

A study by Osaka University found that fat accumulation in liver tumors can predict patient response to immunotherapy. The researchers identified a unique tumor immune microenvironment, known as steatotic HCC, which is associated with high infiltration of immune cells but exhaustion of nearby T cells.

SourceOsaka University·JournalHepatology·TypeExperimental study·DateMay 16, 2022
DJI Air 3 (RC-N2)

DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.

Targeting interleukin-6 could help relieve immunotherapy side effects

Researchers at University of Texas M.D. Anderson Cancer Center identify IL-6 as a key player in immunotherapy toxicity. A novel strategy combining IL-6 blockade with immune checkpoint blockade shows promise in reducing autoimmune side effects while preserving antitumor efficacy.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalCancer Cell·DateMay 9, 2022

Target to make immunotherapy for cancer safer, while more effective

Researchers at Ochsner Health and MD Anderson have discovered that blocking interleukin-6 (IL-6) in lab models improves cancer responses while minimizing inflammation in healthy tissue. By targeting this cytokine, immune checkpoint inhibitors may become more targeted on tumors with fewer side effects.

SourceOchsner Health System·JournalCancer Cell·DateMay 9, 2022

Investigating cancer drug toxicity leads to a critical discovery

Scientists discovered that intermittent dosing of PI3Kδ inhibitors can reduce toxicity while maintaining anti-tumor immunity in patients with head and neck cancers. This finding holds promise for improving treatment outcomes and saving lives.

SourceLa Jolla Institute for Immunology·JournalNature·TypeExperimental study·DateMay 4, 2022

Gut microbiome may alter response to cancer therapy

The composition of microorganisms living in the gut influences response to conventional cancer treatments and novel immunotherapies. Recent studies suggest that targeting the gut microbiome could diminish side effects of chemotherapy, while diet, probiotics, and antibiotic medications may also impact clinical responses.

SourceBrigham and Women's Hospital·JournalJAMA Oncology·DateApr 28, 2022

Researchers shed light on why a certain plant virus is so powerful at fighting cancer

A team of researchers has discovered that cowpea mosaic virus, when injected into a tumor, triggers a powerful immune response, preventing cancer recurrence. The unique protein shell and RNA structure of the virus activate toll-like receptors, leading to increased cytokine production and a prolonged anti-cancer response.

SourceUniversity of California - San Diego·JournalMolecular Pharmaceutics·DateApr 27, 2022
Apple iPad Pro 11-inch (M4)

Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.

Illumination of immune checkpoint LAG3 ‘black box’ could yield new cancer and autoimmune therapies

Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.

SourceUniversity of Pittsburgh·JournalNature Immunology·TypeExperimental study·DateApr 18, 2022

A new toolkit to engineer safe and efficient therapeutic cells

Researchers at Gladstone Institutes and UC San Francisco have developed a comprehensive rule book for designing therapeutic cells with improved specificity and safety. The new receptor system, dubbed SNIPRs, is small enough for cost-effective engineering into human cells and can detect and respond to even small amounts of its target. T...

SourceGladstone Institutes·JournalCell·DateApr 15, 2022

Getting under our skin

Researchers at Harvard Medical School have created spatial maps that show how melanoma cells and immune cells interact as a tumor develops. The maps, which offer insights into the early events in melanoma, reveal signs of immunosuppression and may aid in understanding how to prevent or treat the disease.

SourceHarvard Medical School·JournalCancer Discovery·TypeImaging analysis·DateApr 14, 2022

Moffitt researchers identify key characteristics of immune cells in ovarian cancer

Researchers at Moffitt Cancer Center have discovered that tissue-resident memory T cells are crucial for recognizing tumor cells in ovarian cancer. These T cells arise from circulating T cells and undergo a differentiation process to target cancer cells, providing a potential roadmap for improved immunotherapy options.

SourceH. Lee Moffitt Cancer Center & Research Institute·TypeExperimental study·DateApr 14, 2022
Sky & Telescope Pocket Sky Atlas, 2nd Edition

Sky & Telescope Pocket Sky Atlas, 2nd Edition is a durable star atlas for planning sessions, identifying targets, and teaching celestial navigation.

Immunotherapy plus chemotherapy before surgery improves outcomes for lung cancer patients

Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.

SourceJohns Hopkins Medicine·JournalNew England Journal of Medicine·DateApr 11, 2022

Houston Methodist researchers identify an immunotherapy target to combat glioblastomas

Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.

SourceHouston Methodist·JournalNature Communications·TypeExperimental study·DateApr 5, 2022
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)

Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.

The nanodrug that attacks the cancer twice A single nanoparticle does two jobs: enhancing the effectiveness of chemotherapy and reinvigorating the immune system

Researchers at Tel Aviv University developed a drug delivery system based on lipid nanoparticles that utilize RNA to boost personalized cancer care. The nanodrug enhances chemotherapy effectiveness and reinvigorates the immune system, increasing sensitivity to cancer cells.

SourceTel-Aviv University·JournalScience Advances·DateApr 4, 2022

Omega-3s could boost immunotherapy’s cancer-fighting power

A new study found that omega-3 fatty acid supplementation can broadly improve immunotherapy and other anti-cancer drugs in the clinical setting. In mice, diets enriched with omega-3s blocked tumor growth when combined with immunotherapy or anti-inflammatory treatment, indicating possible synergistic anti-tumor activity.

SourceExperimental Biology·DateApr 1, 2022

Penn Researchers Shorten Manufacturing Time for CAR T Cell Therapy

Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.

SourceUniversity of Pennsylvania School of Medicine·JournalNature Biomedical Engineering·TypeExperimental study·DateMar 29, 2022

Potential therapy may boost chemoimmunotherapy response in bladder cancer

A new therapy combination of immunotherapy, chemotherapy and an anti-inflammatory drug may improve immune response in patients with muscle-invasive bladder cancer. The treatment activates cells to fight tumor growth, potentially leading to better outcomes for patients who don't respond to current treatments.

SourceCedars-Sinai Medical Center·JournalNature Communications·DateMar 28, 2022

Ben-Gurion University researchers and colleagues offer new treatment protocol for advanced head and neck cancer

Researchers at Ben-Gurion University have developed a potential treatment combination for advanced head and neck cancer, which shows promise in pre-clinical models. The therapy involves blocking a specific signaling pathway and sensitizing tumors to immunotherapy, resulting in the disappearance of tumors.

SourceBen-Gurion University of the Negev·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 28, 2022
Garmin GPSMAP 67i with inReach

Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.